RT Journal Article
SR Electronic
T1 Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM<sup>SM</sup> registry
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP 84
DO 10.1186/s40425-019-0567-3
VO 7
IS 1
A1 Fishman, M.
A1 Dutcher, J. P.
A1 Clark, J. I.
A1 Alva, A.
A1 Miletello, G. P.
A1 Curti, B.
A1 Agarwal, Neeraj
A1 Hauke, R.
A1 Mahoney, K. M.
A1 Moon, H.
A1 Treisman, J.
A1 Tykodi, S. S.
A1 Daniels, G.
A1 Morse, M. A.
A1 Wong, M. K. K.
A1 Kaufman, H.
A1 Gregory, N.
A1 McDermott, D. F.
YR 2019
UL http://jitc.bmj.com/content/7/1/84.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.